123-I ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients with movement disorders
Castrejón, Angel Soriano;Vicente, Ana María García;Romera, Montserrat Cortés;Cano, Julia Vaamonde;Marina, Sonia Rodado;García, Victor Manuel Poblete;Solís, Sebastián Ruiz;Rubio, María del Prado Talavera;
brazilian archives of biology and technology2005Vol. 48pp. 115-126
291
castrejon2005123ibrazilian
Abstract
123-I Ioflupane (Datscan®) presynaptic imaging has been shown to have a significant utility in the assessment of patients with movement disorders 123-I Ioflupane SPECT is able to distinguish between Parkinson’s disease (PD) and other forms of parkinsonism without degeneration of the nigrostriatal pathway, including a common movement disorder such as essential tremor, and to assess disease progression in PD and other neurodegenerative disorders involving the substantia nigra. A imagem pré-sináptica através de 123-I Ioflupane (Datscan®) tem mostrado um papel significante na avaliação de pacientes com distúrbios do movimento. 123-I Ioflupane SPECT é capaz de distinguir entre Mal de Parkinson (MP) e outras formas de parkinsonismo sem degenerações da via nigroestriatal incluindo um distúrbio comum de movimento parecido com o tremor essencial e para medir a evolução da doença no Mal de Parkinson e outros distúrbios neurodegenerativos envolvendo a substantia nigra.